This inventor holds 3 USPTO granted patents. Top assignee: Boehringer Ingelheim Gmbh. Active years: 1982-1986.
Company Filing History:
Years Active: 1982-1986
Title: The Innovative Mind of Volkmar Haselbarth: Pioneering Pharmaceuticals in Ingelheim
Introduction
Volkmar Haselbarth, a distinguished inventor based in Ingelheim, Germany, is making waves in the pharmaceutical industry with his groundbreaking patents. With a keen focus on developing advanced drug delivery systems, Haselbarth's contributions are shaping the future of medicine.
Latest Patents
Haselbarth's recent patents showcase his expertise in formulating pharmaceutical dosage units with unique characteristics. One notable invention is the "Retard form of pharmaceuticals with insoluble porous diffusion coatings," which revolutionizes the release rate of active ingredients in medications. This innovative composition features a combination of disintegrating and non-disintegrating cores, each meticulously coated to ensure precise drug delivery.
Career Highlights
Currently employed at Boehringer Ingelheim GmbH, Volkmar Haselbarth is an integral part of the research and development team. His dedication to pushing the boundaries of pharmaceutical technology has led to the successful filing of three patents, cementing his reputation as a visionary inventor in the field.
Collaborations
In his pursuit of excellence, Haselbarth collaborates closely with esteemed colleagues such as Herbert Stricker and Bernhard Freund. Together, they form a dynamic team driving innovation and pushing the boundaries of pharmaceutical research. Their combined expertise and shared vision have resulted in groundbreaking inventions that are transforming the industry.
Conclusion
Volkmar Haselbarth's inventive spirit and relentless pursuit of excellence are evident in his patent portfolio and contributions to the field of pharmaceuticals. Through his innovative approach to drug delivery systems, he is revolutionizing the way medications are formulated and administered. As Haselbarth continues to push the boundaries of innovation, the future of pharmaceuticals looks brighter than ever.